Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

被引：0
作者：
Farastuk Bozorgmehr
Petros Christopoulos
Inn Chung
Jelena Cvetkovic
Manuel Feißt
Johannes Krisam
Marc A. Schneider
Claus Peter Heußel
Michael Kreuter
Daniel W. Müller
Michael Thomas
Stefan Rieken
机构：
[1] Thoraxklinik at University Hospital of Heidelberg,Department of Thoracic Oncology
[2] Member of the German Center for Lung Research DZL,Translational Lung Research Center Heidelberg TLRCH
[3] Institute of Medical Biometry,University Hospital of Heidelberg
[4] Translational Research Unit (STF),Thoraxklinik at University Hospital of Heidelberg
[5] Diagnostic and Interventional Radiology with Nuclear Medicine,Thoraxklinik at University Hospital of Heidelberg
[6] Pneumology and Respiratory Care Medicine,Thoraxklinik at University Hospital of Heidelberg, Center for Interstitial and Rare Lung Diseases
[7] Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital,Department of Radiation Oncology
[8] University Medical Center Göttingen,undefined
来源：
BMC Cancer | / 22卷
关键词：
Extensive disease small cell lung cancer; SCLC; Radioimmuntherapy; Thoracic radiotherapy; Atezolizumab; Anti-PD-L1 monoclonal antibody; First-line therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First -Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
    Novell, Silvia
    Scagliotti, Giorgio
    de Castro, Gilberto, Jr.
    Kiyik, Murat
    Kowalyszyn, Ruben
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Novosiadly, Ruslan D.
    Nguyen, Tuan S.
    Forest, Amelie
    Tang, Shande
    Kambhampati, Siva Rama Prasad
    Cosaert, Jan
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 383 - 389
  • [12] Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study
    Xu, Yanjun
    Huang, Zhiyu
    Chang, Jianhua
    Yu, Yan
    Liu, Chunling
    Li, Juan
    Zhao, Jing
    Lv, Dongqing
    Sun, Si
    Zhang, Qiannan
    Zhou, Yi
    Xu, Jiahui
    Fan, Yun
    LUNG CANCER, 2023, 183
  • [13] AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Scagliotti, Giorgio
    Castro, Gilberto, Jr.
    Kiyik, Murat
    Ruben, Kowalyszyn
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Willey, Richard G.
    Cosaert, Jan
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S601 - S601
  • [14] Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
    Deutsch, E.
    Le Pechoux, C.
    Faivre, L.
    Rivera, S.
    Tao, Y.
    Pignon, J. -P.
    Angokai, M.
    Bahleda, R.
    Deandreis, D.
    Angevin, E.
    Hennequin, C.
    Besse, B.
    Levy, A.
    Soria, J. -C.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1223 - 1229
  • [15] Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
    Felip, E.
    Altorki, N.
    Zhou, C.
    Vallieres, E.
    Martinez-Marti, A.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Goloborodko, O.
    Huang, M.
    Belleli, R.
    McNally, V.
    Srivastava, M. K.
    Bennett, E.
    Gitlitz, B. J.
    Wakelee, H. A.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 907 - 919
  • [16] Fractionated administration of irinotecan and cisplatin for treatment of extensive disease small cell lung cancer: A phase II study
    Takigawa, N
    Fujiwara, K
    Ueoka, H
    Kiura, K
    Tabata, M
    Hiraki, A
    Shibayama, T
    Segawa, Y
    Kamei, H
    Hiraki, S
    Tanimoto, M
    Harada, M
    ANTICANCER RESEARCH, 2003, 23 (1B) : 557 - 560
  • [17] Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) - A study protocol for an open- label, phase II , multicenter study
    Sekino, Yuta
    Ishikawa, Hitoshi
    Kimura, Tomokazu
    Kojima, Takahiro
    Maruo, Kazushi
    Azuma, Haruhito
    Yoshida, Ken
    Kageyama, Yukio
    Ushijima, Hiroki
    Tsuzuki, Toyonori
    Sakurai, Hideyuki
    Nishiyama, Hiroyuki
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 21
  • [18] A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer
    Salgia, Ravi
    Stille, John R.
    Weaver, R. Waide
    McCleod, Michael
    Hamid, Oday
    Polzer, John
    Roberson, Stephanie
    Flynt, Amy
    Spigel, David R.
    LUNG CANCER, 2017, 105 : 7 - 13
  • [19] A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer
    Concannon, Kyle F.
    Glisson, Bonnie S.
    Doebele, Robert C.
    Huang, Chao
    Marotti, Marcelo
    Camidge, D. Ross
    Heymach, John V.
    CLINICAL LUNG CANCER, 2024, 25 (07) : 601 - 611
  • [20] Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
    Langer, Corey J.
    Albert, Istvan
    Ross, Helen J.
    Kovacs, Peter
    Blakely, L. Johnetta
    Pajkos, Gabor
    Somfay, Attila
    Zatloukal, Petr
    Kazarnowicz, Andrzei
    Moezi, Mehdi M.
    Schreeder, Marshall T.
    Schnyder, Judy
    Ao-Baslock, Ada
    Pathak, Ashutosh K.
    Berger, Mark S.
    LUNG CANCER, 2014, 85 (03) : 420 - 428
12345